Consolidation by Any Other Name
The Emergence of Clinically Integrated Networks
ResearchPublished Aug 3, 2020
In this report, the authors offer an initial assessment of clinically integrated networks (CINs) based on interviews with health system executives, describe how health systems (large and small) are using CINs strategically to compete in crowded health care markets, and identify why CINs bear watching by the Federal Trade Commission and the larger health care community.
The Emergence of Clinically Integrated Networks
ResearchPublished Aug 3, 2020
In response to the Patient Protection and Affordable Care Act, health care organizations have sought ways to increase efficiency quickly, improve their ability to coordinate care, and enhance patient outcomes as reflected in publicly available performance measures. One such response has been the emergence of the clinically integrated network (CIN), commonly defined as a group of health care providers that join together to improve patient care, reduce costs, and demonstrate market value.
The Federal Trade Commission (FTC) and U.S. Department of Justice have jointly provided guidance for CINs to determine whether cooperation among these otherwise competing organizations to jointly negotiate fees runs afoul of antitrust law. However, little is known about whether CINs conform to FTC guidance. The FTC does not formally monitor CINs, and health systems wanting to establish a CIN are not required to seek FTC approval. As a result, CINs are basically invisible to regulators and health services researchers, although CINs have the potential to produce negative market effects, such as increasing prices without a corresponding increase in quality.
In this report, the authors offer an initial assessment of CINs based on interviews with health system executives, describe how health systems (large and small) are using CINs strategically to compete in crowded health care markets, and identify why CINs bear watching by the FTC and the larger health care community.
There is no standardization of how CINs are structured or function, and there is only theory, but no evidence, of a positive effect on quality. CINs bear watching because their effects on price and quality are potentially as important as the effects of mergers and acquisitions.
Prior literature provides evidence of the existence of CINs but offers nothing in terms of what they actually look like on the ground.
Health care consolidation via merger and acquisition is considered a threat, but it is possible that the threat is actually greater than recognized if less-visible affiliations (such as CINs) also threaten to drive up health care costs.
If we do not monitor CINs, and if researchers cannot even document in secondary data that they exist, how can we hope to evaluate whether a potential increase in prices is offset by better quality of care?
The research described in this report was conducted by the Access and Delivery Program within RAND Health Care.
This publication is part of the RAND research report series. Research reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND research reports undergo rigorous peer review to ensure high standards for research quality and objectivity.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.